Skip to main content
HIKMA Pharmaceuticals PLC logo

HIKMA Pharmaceuticals PLC — Investor Relations & Filings

Ticker · HIK ISIN · GB00B0LCW083 LEI · 549300BNS685UXH4JI75 IL Manufacturing
Open in API
Filings indexed 827 across all filing types
Latest filing 2023-02-17 Major Shareholding Noti…
Country GB United Kingdom
Listing IL HIK

About HIKMA Pharmaceuticals PLC

https://www.hikma.com/home/

Hikma Pharmaceuticals is a global pharmaceutical company that develops, manufactures, and markets a broad portfolio of pharmaceutical products. The company's offerings include a wide range of generic, branded, specialty, and in-licensed medicines. It is a significant supplier of generic injectable products to hospitals and also provides oral generics and other specialty medications. With a focus on producing high-quality medicines, Hikma aims to make its products accessible to patients and healthcare providers across its key markets in North America, Europe, and the Middle East & North Africa (MENA) region.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is filed under 'RNS Number : 3050Q' for Hikma Pharmaceuticals Plc. The content explicitly details an 'acquisition or disposal of voting rights' by 'BlackRock, Inc.', showing changes in percentage holdings (e.g., previous holding 5.55% total, resulting holding 5.42% total). This type of mandatory disclosure regarding changes in significant share ownership thresholds is specifically covered by the definition for Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the MRQ classification over the general RNS fallback.
2023-02-17 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is a short announcement (3777 characters) identified by the 'RNS Number' header and contains the phrase 'Notice of preliminary results'. It explicitly states that the company 'will announce its preliminary financial results for the year ended 31 December 2022 on Thursday 23 February 2023.' This structure—a brief notice informing the market about the future release date of a substantive report (preliminary results)—fits the definition of a Report Publication Announcement (RPA). It is not the full results (ER or IR) nor the full annual report (10-K).
2023-02-07 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal notification filed with the RNS (Regulatory News Service) of the London Stock Exchange, indicated by the 'RNS Number' and the closing statement referencing RNS as the Primary Information Provider. The content explicitly states the 'Total Voting Rights and Capital' as of a specific date (31 January 2023) and provides the denominator figure for shareholders to use for notification obligations under the FCA's Disclosure Guidance and Transparency Rules. This type of mandatory disclosure regarding the total number of shares with voting rights is a standard regulatory announcement, but it does not fit neatly into the specific categories like 10-K, ER, or DIV. Since it is a mandatory regulatory update that doesn't fit the other specific codes (like DVA for voting *results* or SHA for *issuance*), the most appropriate classification is the general regulatory filing category, RNS.
2023-02-01 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is titled 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' and details a 'Market purchase' of shares by a 'Non-Executive Director' (Deneen Vojta) of Hikma Pharmaceuticals PLC. This content directly corresponds to the definition of Director's Dealing, which reports personal share transactions by company directors and executives. The presence of the RNS Number and the closing statement confirming RNS as the information provider suggests it is a regulatory disclosure, but the specific content points overwhelmingly to Director's Dealing (DIRS).
2023-01-18 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued by Hikma Pharmaceuticals Plc on January 18, 2023. It details changes in voting rights held by BlackRock, Inc., specifically noting an acquisition or disposal of voting rights and providing detailed percentage breakdowns. This structure perfectly matches the definition of a notification regarding changes in significant share ownership levels, which corresponds to the Major Shareholding Notification (MRQ) category. Although it is a regulatory filing, MRQ is the more specific and appropriate classification than the general RNS fallback.
2023-01-18 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued by Hikma Pharmaceuticals Plc on January 17, 2023. It details changes in voting rights held by BlackRock, Inc., specifically noting an acquisition or disposal of voting rights that caused a threshold crossing on 13/01/2023. This type of mandatory disclosure regarding significant changes in share ownership thresholds (usually 3% or 5%) falls directly under the definition of Major Shareholding Notification (MRQ). It is not an earnings release, annual report, or a general regulatory announcement (RNS), but a specific filing type concerning ownership changes.
2023-01-17 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.